The overall objective of the Data and Statistics Core is to provide program project researchers with coordinated and sophisticated data acquisition methodologies and data quality management services, expert statistical and methodological support, and archiving of research data to facilitate the conduct of project clinical trials. The specific objectives of the Data and Statistics Core are: Objective 1: To provide sophisticated data acquisition systems and data quality management services to ensure the timeliness, completeness, accuracy, uniformity, and security of collected clinical and research data. Objective 2: To provide expert statistical and methodological support forthe design, monitoring, and evaluation of the program project clinical trials. Objective 3: To ensure the integrity, safety and accessibility of electronic data through systematic on-site and off-site data archiving and implementation of a data sharing plan. This core is critical to the successful implementation of the individual trials and will leverage shared resources, methodologies, and personnel to reduce costs and increase efficiency across the program project. Data and statistical services will be provided by highly functioning data management and statistical support centers located in Tororo and Kampala, Uganda, and San Francisco, US. The core will be led by Dr. Edwin Charlebois, co-director of the UCSF CenterforAIDS Prevention Studies, UCSF CAPS Methods Core for Data Quality and Management and director ofthe Makerere University-University of California, San Francisco (MU-UCSF) Kampala Data Management Center, a NIH-approved clinical trials data management center in Kampala.

Public Health Relevance

; The Data and Statistics Core will provide access to multiple proven models of researh and clinical trial data management and best-practices via its well established data management and statistics centers in the US and Uganda, allowing for reduced costs and increased efficiency through shared resources, methods and staff cross-trained on all program project trials.

Agency
National Institute of Health (NIH)
Institute
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Type
Research Program Projects (P01)
Project #
5P01HD059454-07
Application #
8706923
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
7
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Wallender, Erika; Vucicevic, Katarina; Jagannathan, Prasanna et al. (2018) Predicting Optimal Dihydroartemisinin-Piperaquine Regimens to Prevent Malaria During Pregnancy for Human Immunodeficiency Virus-Infected Women Receiving Efavirenz. J Infect Dis 217:964-972
Odorizzi, Pamela M; Jagannathan, Prasanna; McIntyre, Tara I et al. (2018) In utero priming of highly functional effector T cell responses to human malaria. Sci Transl Med 10:
Savic, Rada M; Jagannathan, Prasanna; Kajubi, Richard et al. (2018) Intermittent Preventive Treatment for Malaria in Pregnancy: Optimization of Target Concentrations of Dihydroartemisinin-Piperaquine. Clin Infect Dis 67:1079-1088
Jagannathan, Prasanna; Kakuru, Abel; Okiring, Jaffer et al. (2018) Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial. PLoS Med 15:e1002606
Jagannathan, Prasanna; Kajubi, Richard; Aweeka, Francesca T (2018) Response to ""Antiretroviral Therapy With Efavirenz in HIV-Infected Pregnant Women: Understanding the Possible Mechanisms for Drug-Drug Interaction"". Clin Pharmacol Ther 103:571
Conroy, Andrea L; McDonald, Chloe R; Gamble, Joel L et al. (2017) Altered angiogenesis as a common mechanism underlying preterm birth, small for gestational age, and stillbirth in women living with HIV. Am J Obstet Gynecol 217:684.e1-684.e17
Kapisi, James; Kakuru, Abel; Jagannathan, Prasanna et al. (2017) Relationships between infection with Plasmodium falciparum during pregnancy, measures of placental malaria, and adverse birth outcomes. Malar J 16:400
Prahl, Mary; Jagannathan, Prasanna; McIntyre, Tara I et al. (2017) Sex Disparity in Cord Blood FoxP3+ CD4 T Regulatory Cells in Infants Exposed to Malaria In Utero. Open Forum Infect Dis 4:ofx022
Sonoiki, Ebere; Nsanzabana, Christian; Legac, Jennifer et al. (2017) Altered Plasmodium falciparum Sensitivity to the Antiretroviral Protease Inhibitor Lopinavir Associated with Polymorphisms in pfmdr1. Antimicrob Agents Chemother 61:
Kajubi, R; Huang, L; Jagannathan, P et al. (2017) Antiretroviral Therapy With Efavirenz Accentuates Pregnancy-Associated Reduction of Dihydroartemisinin-Piperaquine Exposure During Malaria Chemoprevention. Clin Pharmacol Ther 102:520-528

Showing the most recent 10 out of 59 publications